Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Mapping effector functions of a monoclonal antibody to GD3 by characterization of a mouse-human chimeric antibody.

Chapman PB, Gillies SD, Houghton AN, Reilly RM.

Cancer Immunol Immunother. 1994 Sep;39(3):198-204.

PMID:
7522964
3.

Homophilic binding of mouse monoclonal antibodies against GD3 ganglioside.

Chapman PB, Yuasa H, Houghton AN.

J Immunol. 1990 Aug 1;145(3):891-8.

PMID:
1695649
4.

Immune and nonimmune effector functions of IgG3 mouse monoclonal antibody R24 detecting the disialoganglioside GD3 on the surface of melanoma cells.

Welt S, Carswell EA, Vogel CW, Oettgen HF, Old LJ.

Clin Immunol Immunopathol. 1987 Nov;45(2):214-29.

PMID:
3665201
5.

The role of homophilic binding in anti-tumor antibody R24 recognition of molecular surfaces. Demonstration of an intermolecular beta-sheet interaction between vh domains.

Kaminski MJ, MacKenzie CR, Mooibroek MJ, Dahms TE, Hirama T, Houghton AN, Chapman PB, Evans SV.

J Biol Chem. 1999 Feb 26;274(9):5597-604.

6.

The idiotype (Id) cascade in mice elicited the production of anti-R24 Id and anti-anti-Id monoclonal antibodies with antitumor and protective activity against human melanoma.

Ramos AS, Parise CB, Travassos LR, Han SW, de Campos-Lima PO, de Moraes JZ.

Cancer Sci. 2011 Jan;102(1):64-70. doi: 10.1111/j.1349-7006.2010.01771.x. Epub 2010 Nov 10.

7.

Anti-GD3 monoclonal antibody effects on lymphocytes and antibody-dependent cellular cytotoxicity.

Triozzi PL, Shah JJ, Wang WQ, Aldrich W, Edberg JC, Su K, Carlisle R, Conry R, LoBuglio AF, Forero A.

Cancer Biother Radiopharm. 2006 Dec;21(6):553-60.

PMID:
17257070
8.

Antitumor effects of a novel monoclonal antibody with high binding affinity to ganglioside GD3.

Ohta S, Honda A, Tokutake Y, Yoshida H, Hanai N.

Cancer Immunol Immunother. 1993;36(4):260-6.

PMID:
8439988
9.

Characterization of an Ig VH idiotope that results in specific homophilic binding and increased avidity for antigen.

Yan X, Evans SV, Kaminki MJ, Gillies SD, Reisfeld RA, Houghton AN, Chapman PB.

J Immunol. 1996 Aug 15;157(4):1582-8.

PMID:
8759742
10.

Recombinant antibodies against ganglioside expressed on tumor cells.

Hanai N, Nakamura K, Shitara K.

Cancer Chemother Pharmacol. 2000;46 Suppl:S13-7.

PMID:
10950141
11.

Anti-melanoma effects of R24, a monoclonal antibody against GD3 ganglioside.

Nasi ML, Meyers M, Livingston PO, Houghton AN, Chapman PB.

Melanoma Res. 1997 Aug;7 Suppl 2:S155-62. Review.

PMID:
9578432
12.

Treatment with high dose mouse monoclonal (anti-GD3) antibody R24 in patients with metastatic melanoma.

Bajorin DF, Chapman PB, Wong GY, Cody BV, Cordon-Cardo C, Dantes L, Templeton MA, Scheinberg D, Oettgen HF, Houghton AN.

Melanoma Res. 1992 Dec;2(5-6):355-62.

PMID:
1292783
13.

GD3 ganglioside antibody augments tumoricidal capacity of canine blood mononuclear cells by induction of interleukin 12.

Helfand SC, Dickerson EB, Munson KL, Padilla ML.

Cancer Res. 1999 Jul 1;59(13):3119-27.

14.

Phase I trial of a mouse monoclonal antibody against GD3 ganglioside in patients with melanoma: induction of inflammatory responses at tumor sites.

Vadhan-Raj S, Cordon-Cardo C, Carswell E, Mintzer D, Dantis L, Duteau C, Templeton MA, Oettgen HF, Old LJ, Houghton AN.

J Clin Oncol. 1988 Oct;6(10):1636-48.

PMID:
3171629
15.

Potential to involve multiple effector cells with human recombinant interleukin-2 and antiganglioside monoclonal antibodies in a canine malignant melanoma immunotherapy model.

Helfand SC, Soergel SA, Donner RL, Gan J, Hank JA, Lindstrom MJ, Sondel PM.

J Immunother Emphasis Tumor Immunol. 1994 Oct;16(3):188-97.

PMID:
7834118
17.

A mouse/human chimeric anti-(ganglioside GD3) antibody with enhanced antitumor activities.

Shitara K, Kuwana Y, Nakamura K, Tokutake Y, Ohta S, Miyaji H, Hasegawa M, Hanai N.

Cancer Immunol Immunother. 1993 Jun;36(6):373-80.

PMID:
8500110
18.

Increased lysis of melanoma by in vivo-elicited human lymphokine-activated killer cells after addition of antiganglioside antibodies in vitro.

Harel W, Shau H, Hadley CG, Morgan AC Jr, Reisfeld RA, Cheresh DA, Mitchell MS.

Cancer Res. 1990 Oct 1;50(19):6311-5.

19.

Construction of humanized anti-ganglioside monoclonal antibodies with potent immune effector functions.

Nakamura K, Tanaka Y, Shitara K, Hanai N.

Cancer Immunol Immunother. 2001 Jul;50(5):275-84.

PMID:
11499811
20.

Production and molecular characterization of clinical phase i anti-melanoma mouse IgG3 monoclonal antibody R24.

Kemminer SE, Conradt HS, Nimtz M, Sagi D, Peter-Katalinić J, Diekmann O, Drmić I, Müthing J.

Biotechnol Prog. 2001 Sep-Oct;17(5):809-21.

PMID:
11587568

Supplemental Content

Support Center